Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Phase 1b Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Multiple Subcutaneous Administrations of MWN109 Injection in Chinese Non-Diabetic Participants With Overweight or Obesity

NCT07787728 is registered in ClinicalTrials.gov with Shanghai Minwei Biotechnology Co., Ltd as lead sponsor.

NCT NCT07787728
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07787728 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Phase 1b Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Multiple Subcutaneous Administrations of MWN109 Injection in Chinese Non-Diabetic Participants With Overweight or Obesity
Lead sponsor
Shanghai Minwei Biotechnology Co., Ltd
Phase
Phase 1
Overall status
Completed
Start date
July 14, 2025
Completion date
December 16, 2025
Enrollment
40 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

overweight , obesity